Skip to main content
Log in

ErbB-2 oncoprotein overexpression in breast carcinoma: Inverse correlation with biochemically- and immunohistochemically-determined hormone receptors

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The relationship between erbB-2 oncoprotein overexpression and hormone receptors in breast cancer is controversial. Of 320 infiltrating carcinomas, 75 (23%) showed membranous positivity for erbB-2 protein using CB-11 antibody, with 31 (9.7%) strongly positive. Estrogen and progesterone receptors, determined by both biochemical and immunohistochemical assays, were negative more often in strongly erbB-2 positive tumors, or were positive at lower amounts, than in 56 tumors devoid of CB-11 staining. Strong erbB-2 positivity also correlated with lower patient age, higher histopathologic tumor grade, and higher S phase fraction, but not with tumor size, lymph node involvement, or DNA aneuploidy. Thirty-three lobular carcinomas showed strong erbB-2 positivity as frequently as the overall group (9.1%). Cytoplasmic CB-11 positivity without membrane positivity, thought not to correlate with true erbB-2 positivity, was observed in 189 (59%) tumors with a slight (1–2 +) reaction in 124 (39%) tumors and a moderate-to-strong (3–4 +) reaction in 65 (20%) tumors. Moderate-to-strong cytoplasmic positivity correlated with higher histopathologic grade and negativity for immunohistochemical, but not biochemical, hormone receptors. CB-11 cytoplasmic positivity may have biological significance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. New Engl J Med 326: 1756–1761, 1992

    Google Scholar 

  2. Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Sem Cancer Biol 4: 19–26, 1993

    Google Scholar 

  3. Gullick WJ: The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer; suppl 5: 55–61, 1990

    Google Scholar 

  4. Corbett IP, Henry JA, Angus B, Watchorn CJ, Wilkinson L, Hennessy C, Gullick WJ, Tuzi NL, May FEB, Westley BR, Horne CHW: NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 161: 15–25, 1990

    Google Scholar 

  5. Singleton TP, Niehans GA, Gu F, Litz CE, Hagen K, Qiu Q, Kiang DT, Strickler JG: Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23: 1141–1150, 1992

    Google Scholar 

  6. De Potter CR, Van Daele S, Van De Vijver MJ, Pauwels C, Maertens G, DeBoever J, Vandekerckhove D, Roels H: The expression of theneu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathol 15: 351–362, 1989

    Google Scholar 

  7. Adnane J, Gaudray P, Simon M-P, Simony-Lafontaine J, Jeanteur P, Theillet C: Proto-oncogene amplification and human breast tumor phenotype. Oncogene 4: 1389–1395, 1989

    Google Scholar 

  8. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120–1128, 1989

    Google Scholar 

  9. Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CHW: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087–2090, 1989

    Google Scholar 

  10. Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, Knogler W, Huber J, Zielinski C, Reiner G, Jakesz R, Staffen A, Reiner A, Wrba F, Spona J: HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4: 109–114, 1989

    Google Scholar 

  11. Garcia I, Dietrich P-Y, Aapro M, Vauthier G, Vadas L, Engel E: Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res 49: 6675–6679, 1989

    Google Scholar 

  12. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SAW, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332–4337, 1990

    Google Scholar 

  13. Heintz NH, Leslie KO, Rogers LA, Howard PL: Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 114: 160–163, 1990

    Google Scholar 

  14. Marx D, Schauer A, Reiche C, May A, Ummenhofer L, Reles A, Rauschecker H, Sauer R, Schumacher M: c-erbB2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116: 15–20, 1990

    Google Scholar 

  15. Battifora H, Gaffey M, Esteban J, Mehta P, Bailey A, Faucett C, Niland J: Immunohistochemical assay ofneu/c-erbB-2 oncogene product in paraffin-embedded tissue in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod Pathol 4: 466–474, 1991

    Google Scholar 

  16. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H:ErbB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6: 137–143, 1991

    Google Scholar 

  17. Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650–655, 1991

    Google Scholar 

  18. Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S, Sorvillo JM: Expression ofneu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer: correlation with clinicopathologic parameters. Am J Pathol 138: 1527–1534, 1991

    Google Scholar 

  19. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression ofin situ invasive breast cancer. Hum Pathol 23: 974–979, 1992

    Google Scholar 

  20. Berns EMJJ, Klijn JGM, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA: Prevalence of amplification of the oncogenes c-myc, HER2/neu andint-2 in one thousand human breast tumors: correlation with steroid receptors. Eur J Cancer 28: 697–700, 1992

    Google Scholar 

  21. Ciocca DR, Fujimara FK, Tandon AK, Clark GM, Mark C, Lee-Chen G-J, Pounds GW, Vendely P, Owens MA, Pandian MR, McGuire WL: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Nat Cancer Inst 84: 1279–1282, 1992

    Google Scholar 

  22. Lampe B, Genz T, Maassen V, Mikorey S, Klosterhalfen T: Correlation of cerbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors. Arch Gynecol Obstet 251: 45–50, 1992

    Google Scholar 

  23. Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ, McGuire WL: Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 12: 1965–1972, 1992

    Google Scholar 

  24. Heatley M, Maxwell P, Whiteside C, Toner PG: c-erbB-2 oncogene product expression depends on tumor type and is related to oestrogen receptor and lymph node status in human breast carcinoma. Path Res Pract 189: 261–266, 1993

    Google Scholar 

  25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987

    Google Scholar 

  26. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2 (neu) or c-myc protooncogenes in breast carcinomas correlate with poor shortterm prognosis. Oncogene 1: 423–430, 1987

    Google Scholar 

  27. Ro J, El-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G: c-erbB-2 amplification in nodenegative human breast cancer. Cancer Res 49: 6941–6944, 1989

    Google Scholar 

  28. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, De Bortoli M: c-erbB-2 andras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 47: 833–838, 1991

    Google Scholar 

  29. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438, 1991

    Google Scholar 

  30. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296–3303, 1991

    Google Scholar 

  31. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63: 447–450, 1991

    Google Scholar 

  32. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P: P53 and c-erbB-2 protein expression in breast carcinomas: an immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98: 408–418, 1992

    Google Scholar 

  33. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58: 448–452, 1988

    Google Scholar 

  34. Lacroix H, Iglehart JD, Skinner MA, Kraus MH: Overexpression oferbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4: 145–151, 1989

    Google Scholar 

  35. Zhou D-J, Ahuja H, Cline MJ: Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105–108, 1989

    Google Scholar 

  36. Uehara T, Kaneko Y, Kanda N, Yamamoto T, Higashi Y, Nomoto C, Izumo T, Takayama S, Sakurai M: c-erbB-2 and c-erbA-1 (ear-1) gene amplification and c-erbB-2 protein expression in Japanese breast cancers: their relationship to the histology and other disease parameters. Jpn J Cancer Res 81: 620–624, 1990

    Google Scholar 

  37. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51: 944–948, 1991

    Google Scholar 

  38. Charpin C, Devictor B, Bonnier P, Andrac L, Lavaut M-N, Allasia C, Piana L: Expression of HER-2/neu oncogene in breast cancer: correlation of quantitative immunocytochemistry and prognostic factors. Int J Oncol 1: 815–823, 1992

    Google Scholar 

  39. Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, Meli S, Boracchi P, Testolin A, La Malfa G, Pozza F: Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10: 686–695, 1992

    Google Scholar 

  40. Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA, Preisler HD: c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res 52: 2597–2602, 1992

    Google Scholar 

  41. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP: HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12: 419–426, 1992

    Google Scholar 

  42. Kreipe H, Feist H, Fischer L, Felgner J, Heidorn K, Mettler L, Parwaresch R: Amplification of c-myc but not of c-erbB-2 is associated with high proliferation capacity in breast cancers. Cancer Res 53: 1956–1961, 1993

    Google Scholar 

  43. Bloom HJG, Richardson WW: Histologic grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377, 1957

    Google Scholar 

  44. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 19: 403–410, 1991

    Google Scholar 

  45. Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, Lennard TJW, Angus B, Horne CHW: Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 163: 105–110, 1991

    Google Scholar 

  46. Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I, Mizukami Y: c-erbB-2 oncoprotein expressionversus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69: 2953–2960, 1992

    Google Scholar 

  47. Tommasi S, Paradiso A, Mangia A, Barletta A, Simone G, Slamon DJ, De Lena M: Biological correlation between HER-2/neu and proliferative activity in human breast cancer. Anticancer Res 11: 1395–1400, 1991

    Google Scholar 

  48. Baak JPA, Chin D, van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS: Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab Invest 64: 215–223, 1991

    Google Scholar 

  49. Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10: 1044–1048, 1992

    Google Scholar 

  50. Soomro S, Shousha S, Taylor P, Shepard HM, Feldmann M: c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol 44: 211–214, 1991

    Google Scholar 

  51. Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM: c-erbB-2 oncogene protein inin situ and invasive lobular breast neoplasia. Cancer 68: 331–334, 1991

    Google Scholar 

  52. Somerville JE, Clarke LA, Biggart JD: c-erbB-2 overexpression and histological type ofin situ and invasive breast carcinoma. J Clin Pathol 45: 16–20, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keshgegian, A.A. ErbB-2 oncoprotein overexpression in breast carcinoma: Inverse correlation with biochemically- and immunohistochemically-determined hormone receptors. Breast Cancer Res Tr 35, 201–210 (1995). https://doi.org/10.1007/BF00668210

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00668210

Key words

Navigation